-
1
-
-
77953569296
-
Centromere localization of INCENP-Aurora B is sufficient to support spindle checkpoint function
-
Becker M, Stolz A, Ertych N and Bastians H. Centromere localization of INCENP-Aurora B is sufficient to support spindle checkpoint function. Cell Cycle. 2010; 9(7):1360-1372.
-
(2010)
Cell Cycle
, vol.9
, Issue.7
, pp. 1360-1372
-
-
Becker, M.1
Stolz, A.2
Ertych, N.3
Bastians, H.4
-
2
-
-
79951778220
-
Two TPX2-dependent switches control the activity of Aurora A
-
Xu X, Wang X, Xiao Z, Li Y and Wang Y. Two TPX2-dependent switches control the activity of Aurora A. PLoS One. 2011; 6(2):e16757.
-
(2011)
PLoS One
, vol.6
, Issue.2
-
-
Xu, X.1
Wang, X.2
Xiao, Z.3
Li, Y.4
Wang, Y.5
-
3
-
-
84871880725
-
Studying the roles of Aurora-C kinase during meiosis in mouse oocytes
-
Yang KT, Lin YN, Li SK and Tang TK. Studying the roles of Aurora-C kinase during meiosis in mouse oocytes. Methods Mol Biol. 2013; 957:189-202.
-
(2013)
Methods Mol Biol
, vol.957
, pp. 189-202
-
-
Yang, K.T.1
Lin, Y.N.2
Li, S.K.3
Tang, T.K.4
-
4
-
-
0037386929
-
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer
-
Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV and Cheng JQ. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res. 2003; 9(4):1420-1426.
-
(2003)
Clin Cancer Res
, vol.9
, Issue.4
, pp. 1420-1426
-
-
Gritsko, T.M.1
Coppola, D.2
Paciga, J.E.3
Yang, L.4
Sun, M.5
Shelley, S.A.6
Fiorica, J.V.7
Nicosia, S.V.8
Cheng, J.Q.9
-
5
-
-
0030962953
-
A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines
-
Sen S, Zhou H and White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene. 1997; 14(18):2195-2200.
-
(1997)
Oncogene
, vol.14
, Issue.18
, pp. 2195-2200
-
-
Sen, S.1
Zhou, H.2
White, R.A.3
-
6
-
-
18044391525
-
Aurora kinases, aneuploidy and cancer, a coincidence or a real link?
-
Giet R, Petretti C and Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol. 2005; 15(5):241-250.
-
(2005)
Trends Cell Biol
, vol.15
, Issue.5
, pp. 241-250
-
-
Giet, R.1
Petretti, C.2
Prigent, C.3
-
7
-
-
0038341158
-
The Aurora kinases: role in cell transformation and tumorigenesis
-
Katayama H, Brinkley WR and Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 2003; 22(4):451-464.
-
(2003)
Cancer Metastasis Rev
, vol.22
, Issue.4
, pp. 451-464
-
-
Katayama, H.1
Brinkley, W.R.2
Sen, S.3
-
8
-
-
9144251019
-
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53
-
Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA and Sen S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004; 36(1):55-62.
-
(2004)
Nat Genet
, vol.36
, Issue.1
, pp. 55-62
-
-
Katayama, H.1
Sasai, K.2
Kawai, H.3
Yuan, Z.M.4
Bondaruk, J.5
Suzuki, F.6
Fujii, S.7
Arlinghaus, R.B.8
Czerniak, B.A.9
Sen, S.10
-
9
-
-
1642556824
-
Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells
-
Yang H, Ou CC, Feldman RI, Nicosia SV, Kruk PA and Cheng JQ. Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res. 2004; 64(2):463-467.
-
(2004)
Cancer Res
, vol.64
, Issue.2
, pp. 463-467
-
-
Yang, H.1
Ou, C.C.2
Feldman, R.I.3
Nicosia, S.V.4
Kruk, P.A.5
Cheng, J.Q.6
-
10
-
-
17144362848
-
Progress in the development of selective inhibitors of Aurora kinases
-
Mortlock A, Keen NJ, Jung FH, Heron NM, Foote KM, Wilkinson R and Green S. Progress in the development of selective inhibitors of Aurora kinases. Curr Top Med Chem. 2005; 5(2):199-213.
-
(2005)
Curr Top Med Chem
, vol.5
, Issue.2
, pp. 199-213
-
-
Mortlock, A.1
Keen, N.J.2
Jung, F.H.3
Heron, N.M.4
Foote, K.M.5
Wilkinson, R.6
Green, S.7
-
11
-
-
0013057087
-
Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores
-
Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N and Taylor SS. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol. 2003; 161(2):267-280.
-
(2003)
J Cell Biol
, vol.161
, Issue.2
, pp. 267-280
-
-
Ditchfield, C.1
Johnson, V.L.2
Tighe, A.3
Ellston, R.4
Haworth, C.5
Johnson, T.6
Mortlock, A.7
Keen, N.8
Taylor, S.S.9
-
12
-
-
0038746733
-
The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint
-
Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL and Peters JM. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol. 2003; 161(2):281-294.
-
(2003)
J Cell Biol
, vol.161
, Issue.2
, pp. 281-294
-
-
Hauf, S.1
Cole, R.W.2
Laterra, S.3
Zimmer, C.4
Schnapp, G.5
Walter, R.6
Heckel, A.7
van Meel, J.8
Rieder, C.L.9
Peters, J.M.10
-
13
-
-
33749409412
-
Validating Aurora B as an anti-cancer drug target
-
Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ and Taylor SS. Validating Aurora B as an anti-cancer drug target. J Cell Sci. 2006; 119(Pt 17):3664-3675.
-
(2006)
J Cell Sci
, vol.119
, Issue.PART 17
, pp. 3664-3675
-
-
Girdler, F.1
Gascoigne, K.E.2
Eyers, P.A.3
Hartmuth, S.4
Crafter, C.5
Foote, K.M.6
Keen, N.J.7
Taylor, S.S.8
-
14
-
-
2342639645
-
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
-
Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM and Miller KM. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004; 10(3):262-267.
-
(2004)
Nat Med
, vol.10
, Issue.3
, pp. 262-267
-
-
Harrington, E.A.1
Bebbington, D.2
Moore, J.3
Rasmussen, R.K.4
Ajose-Adeogun, A.O.5
Nakayama, T.6
Graham, J.A.7
Demur, C.8
Hercend, T.9
Diu-Hercend, A.10
Su, M.11
Golec, J.M.12
Miller, K.M.13
-
15
-
-
79952209771
-
Update on Aurora Kinase Targeted Therapeutics in Oncology
-
Green MR, Woolery JE and Mahadevan D. Update on Aurora Kinase Targeted Therapeutics in Oncology. Expert Opin Drug Discov. 2011; 6(3):291-307.
-
(2011)
Expert Opin Drug Discov
, vol.6
, Issue.3
, pp. 291-307
-
-
Green, M.R.1
Woolery, J.E.2
Mahadevan, D.3
-
16
-
-
34247259822
-
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
-
Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A. 2007; 104(10):4106-4111.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, Issue.10
, pp. 4106-4111
-
-
Manfredi, M.G.1
Ecsedy, J.A.2
Meetze, K.A.3
Balani, S.K.4
Burenkova, O.5
Chen, W.6
Galvin, K.M.7
Hoar, K.M.8
Huck, J.J.9
Leroy, P.J.10
Ray, E.T.11
Sells, T.B.12
Stringer, B.13
Stroud, S.G.14
Vos, T.J.15
Weatherhead, G.S.16
-
17
-
-
34247603906
-
Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase
-
Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem. 2007; 50(9):2213-2224.
-
(2007)
J Med Chem
, vol.50
, Issue.9
, pp. 2213-2224
-
-
Mortlock, A.A.1
Foote, K.M.2
Heron, N.M.3
Jung, F.H.4
Pasquet, G.5
Lohmann, J.J.6
Warin, N.7
Renaud, F.8
De Savi, C.9
Roberts, N.J.10
Johnson, T.11
Dousson, C.B.12
Hill, G.B.13
Perkins, D.14
Hatter, G.15
Wilkinson, R.W.16
-
18
-
-
84859405151
-
The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells
-
Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, Ecsedy J, Zaika A, Rau TT, Schneider-Stock R, Belkhiri A and El-Rifai W. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther. 2012; 11(3):763-774.
-
(2012)
Mol Cancer Ther
, vol.11
, Issue.3
, pp. 763-774
-
-
Sehdev, V.1
Peng, D.2
Soutto, M.3
Washington, M.K.4
Revetta, F.5
Ecsedy, J.6
Zaika, A.7
Rau, T.T.8
Schneider-Stock, R.9
Belkhiri, A.10
El-Rifai, W.11
-
19
-
-
84859725892
-
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells
-
Borges KS, Castro-Gamero AM, Moreno DA, da Silva Silveira V, Brassesco MS, de Paula Queiroz RG, de Oliveira HF, Carlotti CG, Jr., Scrideli CA and Tone LG. Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. J Cancer Res Clin Oncol. 2012; 138(3):405-414.
-
(2012)
J Cancer Res Clin Oncol
, vol.138
, Issue.3
, pp. 405-414
-
-
Borges, K.S.1
Castro-Gamero, A.M.2
Moreno, D.A.3
da Silva Silveira, V.4
Brassesco, M.S.5
de Paula Queiroz, R.G.6
de Oliveira, H.F.7
Carlotti Jr., C.G.8
Scrideli, C.A.9
Tone, L.G.10
-
20
-
-
79952565110
-
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
-
Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, Manziolli A, Persky DO, Miller TP and Mahadevan D. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol. 2011; 81(7):881-890.
-
(2011)
Biochem Pharmacol
, vol.81
, Issue.7
, pp. 881-890
-
-
Qi, W.1
Cooke, L.S.2
Liu, X.3
Rimsza, L.4
Roe, D.J.5
Manziolli, A.6
Persky, D.O.7
Miller, T.P.8
Mahadevan, D.9
-
21
-
-
84873094495
-
Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines
-
Muscal JA, Scorsone KA, Zhang L, Ecsedy JA and Berg SL. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs. 2013; 31(1):39-45.
-
(2013)
Invest New Drugs
, vol.31
, Issue.1
, pp. 39-45
-
-
Muscal, J.A.1
Scorsone, K.A.2
Zhang, L.3
Ecsedy, J.A.4
Berg, S.L.5
-
22
-
-
79957528550
-
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
-
Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, Giles FJ and Carew JS. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med. 2011; 15(10):2057-2070.
-
(2011)
J Cell Mol Med
, vol.15
, Issue.10
, pp. 2057-2070
-
-
Kelly, K.R.1
Ecsedy, J.2
Medina, E.3
Mahalingam, D.4
Padmanabhan, S.5
Nawrocki, S.T.6
Giles, F.J.7
Carew, J.S.8
-
23
-
-
52949089050
-
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies
-
Vainchenker W, Dusa A and Constantinescu SN. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin Cell Dev Biol. 2008; 19(4):385-393.
-
(2008)
Semin Cell Dev Biol
, vol.19
, Issue.4
, pp. 385-393
-
-
Vainchenker, W.1
Dusa, A.2
Constantinescu, S.N.3
-
24
-
-
0035799531
-
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
-
Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A and Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001; 20(20):2499-2513.
-
(2001)
Oncogene
, vol.20
, Issue.20
, pp. 2499-2513
-
-
Garcia, R.1
Bowman, T.L.2
Niu, G.3
Yu, H.4
Minton, S.5
Muro-Cacho, C.A.6
Cox, C.E.7
Falcone, R.8
Fairclough, R.9
Parsons, S.10
Laudano, A.11
Gazit, A.12
Levitzki, A.13
Kraker, A.14
Jove, R.15
-
25
-
-
1042302005
-
The STATs of cancer-new molecular targets come of age
-
Yu H and Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004; 4(2):97-105.
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.2
, pp. 97-105
-
-
Yu, H.1
Jove, R.2
-
26
-
-
0036093058
-
Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival
-
Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H and Wetzler M. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002; 99(1):252-257.
-
(2002)
Blood
, vol.99
, Issue.1
, pp. 252-257
-
-
Benekli, M.1
Xia, Z.2
Donohue, K.A.3
Ford, L.A.4
Pixley, L.A.5
Baer, M.R.6
Baumann, H.7
Wetzler, M.8
-
27
-
-
84875378326
-
The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications
-
Quintas-Cardama A. The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications. Leuk Res. 2013; 37(4):465-472.
-
(2013)
Leuk Res
, vol.37
, Issue.4
, pp. 465-472
-
-
Quintas-Cardama, A.1
-
28
-
-
77950684805
-
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
-
Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115(15):3109-3117.
-
(2010)
Blood
, vol.115
, Issue.15
, pp. 3109-3117
-
-
Quintas-Cardama, A.1
Vaddi, K.2
Liu, P.3
Manshouri, T.4
Li, J.5
Scherle, P.A.6
Caulder, E.7
Wen, X.8
Li, Y.9
Waeltz, P.10
Rupar, M.11
Burn, T.12
Lo, Y.13
Kelley, J.14
Covington, M.15
Shepard, S.16
-
29
-
-
84861216420
-
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
-
Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM and Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012; 119(20):4614-4618.
-
(2012)
Blood
, vol.119
, Issue.20
, pp. 4614-4618
-
-
Eghtedar, A.1
Verstovsek, S.2
Estrov, Z.3
Burger, J.4
Cortes, J.5
Bivins, C.6
Faderl, S.7
Ferrajoli, A.8
Borthakur, G.9
George, S.10
Scherle, P.A.11
Newton, R.C.12
Kantarjian, H.M.13
Ravandi, F.14
-
30
-
-
84866334399
-
Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors
-
Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E and Lawrence NJ. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. J Med Chem. 2012; 55(17):7392-7416.
-
(2012)
J Med Chem
, vol.55
, Issue.17
, pp. 7392-7416
-
-
Lawrence, H.R.1
Martin, M.P.2
Luo, Y.3
Pireddu, R.4
Yang, H.5
Gevariya, H.6
Ozcan, S.7
Zhu, J.Y.8
Kendig, R.9
Rodriguez, M.10
Elias, R.11
Cheng, J.Q.12
Sebti, S.M.13
Schonbrunn, E.14
Lawrence, N.J.15
-
31
-
-
10344236486
-
Aurora-kinase inhibitors as anticancer agents
-
Keen N and Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 2004; 4(12):927-936.
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.12
, pp. 927-936
-
-
Keen, N.1
Taylor, S.2
-
32
-
-
41549122837
-
Aurora kinases as anticancer drug targets
-
Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Jr. and Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008; 14(6):1639-1648.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.6
, pp. 1639-1648
-
-
Gautschi, O.1
Heighway, J.2
Mack, P.C.3
Purnell, P.R.4
Lara Jr., P.N.5
Gandara, D.R.6
-
33
-
-
82855180125
-
Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck
-
Aug
-
Hoellein A PA, von Keitz F, Schoeffmann S, Piontek G, Rudelius M, Baumgart A, Wagenpfeil S, Peschel C, Dechow T, Bier H, Keller U and Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck. Oncotarget. 2011; Aug 2(8):599-609.
-
(2011)
Oncotarget
, vol.2
, Issue.8
, pp. 599-609
-
-
Hoellein, A.P.A.1
von Keitz, F.2
Schoeffmann, S.3
Piontek, G.4
Rudelius, M.5
Baumgart, A.6
Wagenpfeil, S.7
Peschel, C.8
Dechow, T.9
Bier, H.10
Keller, U.11
-
34
-
-
79956035239
-
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy
-
Rao B vLI, Higgins M, Campbel J, Thompson AM, Lane DP, Lain S. Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy. Oncotarget. 2010; No;1(7):639-650.
-
(2010)
Oncotarget
, vol.1
, Issue.7
, pp. 639-650
-
-
Rao, B.1
van Leeuwen, I.M.2
Higgins, M.3
Campbel, J.4
Thompson, A.M.5
Lane, D.P.6
Lain, S.7
-
35
-
-
26244463218
-
Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling inducesapoptosis and cell cycle arrest of colon carcinoma cells
-
Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, Hamilton SR and Amin HM. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling inducesapoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 2005; 167(4):969-980.
-
(2005)
Am J Pathol
, vol.167
, Issue.4
, pp. 969-980
-
-
Lin, Q.1
Lai, R.2
Chirieac, L.R.3
Li, C.4
Thomazy, V.A.5
Grammatikakis, I.6
Rassidakis, G.Z.7
Zhang, W.8
Fujio, Y.9
Kunisada, K.10
Hamilton, S.R.11
Amin, H.M.12
-
36
-
-
80555154949
-
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies
-
Jun 2
-
Passamonti F MM, Caramazza D, Cazzola M. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget. 2011; Jun2;(6):485-490.
-
(2011)
Oncotarget
, Issue.6
, pp. 485-490
-
-
Passamonti, F.M.M.1
Caramazza, D.2
Cazzola, M.3
-
37
-
-
53349101074
-
Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells
-
Wan XB, Long ZJ, Yan M, Xu J, Xia LP, Liu L, Zhao Y, Huang XF, Wang XR, Zhu XF, Hong MH and Liu Q. Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis. 2008; 29(10):1930-1937.
-
(2008)
Carcinogenesis
, vol.29
, Issue.10
, pp. 1930-1937
-
-
Wan, X.B.1
Long, Z.J.2
Yan, M.3
Xu, J.4
Xia, L.P.5
Liu, L.6
Zhao, Y.7
Huang, X.F.8
Wang, X.R.9
Zhu, X.F.10
Hong, M.H.11
Liu, Q.12
-
38
-
-
40049093105
-
Inhibition of signal transducer and activator of transcription 3 expression by RNA interference suppresses invasion through inducing anoikis in human colon cancer cells
-
Fan Y, Zhang YL, Wu Y, Zhang W, Wang YH, Cheng ZM and Li H. Inhibition of signal transducer and activator of transcription 3 expression by RNA interference suppresses invasion through inducing anoikis in human colon cancer cells. World J Gastroenterol. 2008; 14(3):428-434.
-
(2008)
World J Gastroenterol
, vol.14
, Issue.3
, pp. 428-434
-
-
Fan, Y.1
Zhang, Y.L.2
Wu, Y.3
Zhang, W.4
Wang, Y.H.5
Cheng, Z.M.6
Li, H.7
-
39
-
-
1842836011
-
Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and-independent growth of human tumor cells
-
Laird AD, Li G, Moss KG, Blake RA, Broome MA, Cherrington JM and Mendel DB. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and-independent growth of human tumor cells. Mol Cancer Ther. 2003; 2(5):461-469.
-
(2003)
Mol Cancer Ther
, vol.2
, Issue.5
, pp. 461-469
-
-
Laird, A.D.1
Li, G.2
Moss, K.G.3
Blake, R.A.4
Broome, M.A.5
Cherrington, J.M.6
Mendel, D.B.7
-
40
-
-
77950915903
-
The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases
-
Hitoshi Y, Lin N, Payan DG and Markovtsov V. The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. Int J Hematol. 2010; 91(2):189-200.
-
(2010)
Int J Hematol
, vol.91
, Issue.2
, pp. 189-200
-
-
Hitoshi, Y.1
Lin, N.2
Payan, D.G.3
Markovtsov, V.4
-
41
-
-
84865681647
-
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or-refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
-
Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H and Schilder RJ. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or-refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol. 2012; 127(1):63-69.
-
(2012)
Gynecol Oncol
, vol.127
, Issue.1
, pp. 63-69
-
-
Matulonis, U.A.1
Sharma, S.2
Ghamande, S.3
Gordon, M.S.4
Del Prete, S.A.5
Ray-Coquard, I.6
Kutarska, E.7
Liu, H.8
Fingert, H.9
Zhou, X.10
Danaee, H.11
Schilder, R.J.12
-
42
-
-
84875373630
-
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment
-
Qi W, Spier C, Liu X, Agarwal A, Cooke LS, Persky DO, Chen D, Miller TP and Mahadevan D. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res. 2013; 37(4):434-439.
-
(2013)
Leuk Res
, vol.37
, Issue.4
, pp. 434-439
-
-
Qi, W.1
Spier, C.2
Liu, X.3
Agarwal, A.4
Cooke, L.S.5
Persky, D.O.6
Chen, D.7
Miller, T.P.8
Mahadevan, D.9
-
43
-
-
60549088370
-
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity
-
Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O'Brien MA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem. 2009; 52(2):379-388.
-
(2009)
J Med Chem
, vol.52
, Issue.2
, pp. 379-388
-
-
Howard, S.1
Berdini, V.2
Boulstridge, J.A.3
Carr, M.G.4
Cross, D.M.5
Curry, J.6
Devine, L.A.7
Early, T.R.8
Fazal, L.9
Gill, A.L.10
Heathcote, M.11
Maman, S.12
Matthews, J.E.13
Mcmenamin, R.L.14
Navarro, E.F.15
O'Brien, M.A.16
-
44
-
-
77957201111
-
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
-
Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M, Yao H, Reule M, Smyth T, Lyons JF, Thompson NT, Ashihara E, Ottmann OG and Maekawa T. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood. 2010; 116(12):2089-2095.
-
(2010)
Blood
, vol.116
, Issue.12
, pp. 2089-2095
-
-
Tanaka, R.1
Squires, M.S.2
Kimura, S.3
Yokota, A.4
Nagao, R.5
Yamauchi, T.6
Takeuchi, M.7
Yao, H.8
Reule, M.9
Smyth, T.10
Lyons, J.F.11
Thompson, N.T.12
Ashihara, E.13
Ottmann, O.G.14
Maekawa, T.15
-
45
-
-
84860485132
-
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
-
Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H and Judson I. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol. 2012; 23(5):1307-1313.
-
(2012)
Ann Oncol
, vol.23
, Issue.5
, pp. 1307-1313
-
-
Arkenau, H.T.1
Plummer, R.2
Molife, L.R.3
Olmos, D.4
Yap, T.A.5
Squires, M.6
Lewis, S.7
Lock, V.8
Yule, M.9
Lyons, J.10
Calvert, H.11
Judson, I.12
-
46
-
-
3843142735
-
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
-
Levis M, Pham R, Smith BD and Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004; 104(4):1145-1150.
-
(2004)
Blood
, vol.104
, Issue.4
, pp. 1145-1150
-
-
Levis, M.1
Pham, R.2
Smith, B.D.3
Small, D.4
-
47
-
-
84874368903
-
Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F
-
Gabler K, Rolvering C, Kaczor J, Eulenfeld R, Mendez SA, Berchem G, Palissot V, Behrmann I and Haan C. Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F. J Cell Mol Med. 2013; 17(2):265-276.
-
(2013)
J Cell Mol Med
, vol.17
, Issue.2
, pp. 265-276
-
-
Gabler, K.1
Rolvering, C.2
Kaczor, J.3
Eulenfeld, R.4
Mendez, S.A.5
Berchem, G.6
Palissot, V.7
Behrmann, I.8
Haan, C.9
-
48
-
-
77949535491
-
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
-
Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J and Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010; 115(6):1131-1136.
-
(2010)
Blood
, vol.115
, Issue.6
, pp. 1131-1136
-
-
Santos, F.P.1
Kantarjian, H.M.2
Jain, N.3
Manshouri, T.4
Thomas, D.A.5
Garcia-Manero, G.6
Kennedy, D.7
Estrov, Z.8
Cortes, J.9
Verstovsek, S.10
-
49
-
-
77954686021
-
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
-
Gorgun G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010; 115(25):5202-5213.
-
(2010)
Blood
, vol.115
, Issue.25
, pp. 5202-5213
-
-
Gorgun, G.1
Calabrese, E.2
Hideshima, T.3
Ecsedy, J.4
Perrone, G.5
Mani, M.6
Ikeda, H.7
Bianchi, G.8
Hu, Y.9
Cirstea, D.10
Santo, L.11
Tai, Y.T.12
Nahar, S.13
Zheng, M.14
Bandi, M.15
Carrasco, R.D.16
-
50
-
-
33947199328
-
K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling
-
Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V and Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res. 2007; 67(5):2098-2106.
-
(2007)
Cancer Res
, vol.67
, Issue.5
, pp. 2098-2106
-
-
Campbell, P.M.1
Groehler, A.L.2
Lee, K.M.3
Ouellette, M.M.4
Khazak, V.5
Der, C.J.6
-
51
-
-
77957833800
-
The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane
-
Berndt N, Yang H, Trinczek B, Betzi S, Zhang Z, Wu B, Lawrence NJ, Pellecchia M, Schonbrunn E, Cheng JQ and Sebti SM. The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ. 2010; 17(11):1795-1804.
-
(2010)
Cell Death Differ
, vol.17
, Issue.11
, pp. 1795-1804
-
-
Berndt, N.1
Yang, H.2
Trinczek, B.3
Betzi, S.4
Zhang, Z.5
Wu, B.6
Lawrence, N.J.7
Pellecchia, M.8
Schonbrunn, E.9
Cheng, J.Q.10
Sebti, S.M.11
-
52
-
-
0033967589
-
Enrichment for submitotic cell populations using flow cytometry
-
Widrow RJ and Laird CD. Enrichment for submitotic cell populations using flow cytometry. Cytometry. 2000; 39(2):126-130.
-
(2000)
Cytometry
, vol.39
, Issue.2
, pp. 126-130
-
-
Widrow, R.J.1
Laird, C.D.2
-
53
-
-
79955504184
-
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice
-
Balasis ME, Forinash KD, Chen YA, Fulp WJ, Coppola D, Hamilton AD, Cheng JQ and Sebti SM. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res. 2011; 17(9):2852-2862.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.9
, pp. 2852-2862
-
-
Balasis, M.E.1
Forinash, K.D.2
Chen, Y.A.3
Fulp, W.J.4
Coppola, D.5
Hamilton, A.D.6
Cheng, J.Q.7
Sebti, S.M.8
-
54
-
-
84867120378
-
RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer
-
Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schonbrunn E, Lawrence NJ and Sebti SM. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res. 2012; 72(19):5025-5034.
-
(2012)
Cancer Res
, vol.72
, Issue.19
, pp. 5025-5034
-
-
Patel, R.A.1
Forinash, K.D.2
Pireddu, R.3
Sun, Y.4
Sun, N.5
Martin, M.P.6
Schonbrunn, E.7
Lawrence, N.J.8
Sebti, S.M.9
|